Abiomed (NASDAQ: ABMD) is a pioneer and global leader in healthcare technology and innovation, with a mission of RECOVERING HEARTS AND SAVING LIVES. Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.
Type
Public
HQ
Danvers, US
Employees
589 (est)
ABIOMED is headquartered in Danvers, US

ABIOMED Locations

Danvers, US
Aachen, DE

ABIOMED Metrics

ABIOMED Summary

Market capitalization

$4.92 B

Closing share price

$116
ABIOMED's current market capitalization is $4.92 B.

ABIOMED Financials

ABIOMED's revenue is $230 M in FY, 2015 which is 25.41% increase from the previous period.
FY, 2014FY, 2015

Revenue

$184 M$230 M

Gross profit

$146 M$190 M

Operating income

$8.36 M$28.7 M

Operating expense total

$138 M$162 M

Net Income

$7.35 M$114 M

Operating cash flow

$11.5 M$1.49 M

    ABIOMED Market Value History

    ABIOMED Online Presence

    ABIOMED Company Life

    You may also be interested in